B. Metzler seel. Sohn & Co. AG Sells 4,539 Shares of Amgen Inc. $AMGN

B. Metzler seel. Sohn & Co. AG trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,041 shares of the medical research company's stock after selling 4,539 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Amgen were worth $14,137,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Anfield Capital Management LLC raised its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC boosted its position in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after buying an additional 55 shares during the period. Tower View Wealth Management LLC grew its stake in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after buying an additional 63 shares during the last quarter. Manning & Napier Advisors LLC grew its stake in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after buying an additional 32 shares during the last quarter. Finally, Evergreen Advisors LLC purchased a new position in shares of Amgen in the first quarter worth about $37,000. Institutional investors own 76.50% of the company's stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New evidence that Amgen’s cholesterol drug Repatha reduced the risk of death among patients at high risk of heart attack or stroke strengthens the drug’s clinical profile and could support broader use, sales growth and reimbursement. Amgen's Repatha reduces risk of death in people at high risk of heart attack or stroke
• Positive Sentiment: Commentary highlighted Repatha’s potentially significant cardiovascular opportunity, adding to investor enthusiasm about a product that could become an important long-term growth driver beyond Amgen’s current results. Jim Cramer on Amgen's cardiovascular opportunity
• Positive Sentiment: Analyst H. Engel of Erste Group raised the firm’s 2027 EPS estimate to $24.43 from $23.50, signaling improved expectations for Amgen’s earnings trajectory, although the firm maintained a Hold rating.
• Neutral Sentiment: Amgen will present at the Wells Fargo Healthcare Conference, giving investors a potential update on its pipeline, commercial outlook and strategy. The announcement itself contains no new financial guidance. Amgen to present at the 2026 Wells Fargo Healthcare Conference
• Negative Sentiment: U.K. regulators suspended Tavneos for new patients and halted its sale after determining that the main supporting study contained unreliable data. The action threatens sales of the rare-disease treatment and raises the risk of additional regulatory scrutiny or restrictions in other markets. UK regulator suspends Amgen's Tavneos for new patients

Analyst Ratings Changes

A number of research firms have recently weighed in on AMGN. Morgan Stanley reissued an "overweight" rating and issued a $362.00 target price on shares of Amgen in a research note on Wednesday, August 19th. Barclays raised their price target on Amgen from $360.00 to $380.00 and gave the stock an "equal weight" rating in a research report on Friday, August 14th. Guggenheim boosted their price objective on Amgen from $343.00 to $388.00 and gave the company a "neutral" rating in a research report on Monday, August 10th. Cantor Fitzgerald increased their price objective on Amgen from $350.00 to $400.00 and gave the company a "neutral" rating in a research note on Tuesday, August 18th. Finally, Piper Sandler raised their target price on shares of Amgen from $427.00 to $457.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $380.43.

Amgen Price Performance

AMGN opened at $442.84 on Thursday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a market capitalization of $239.41 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 3.16 and a beta of 0.43. The stock's 50 day moving average price is $393.99 and its 200-day moving average price is $366.13. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter last year, the firm posted $6.02 earnings per share. The firm's revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's payout ratio is presently 62.65%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last quarter. Company insiders own 0.85% of the company's stock.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source